City Therapeutics is a clinical-stage biotechnology company developing RNA interference (RNAi) therapies to treat disease by silencing target genes. The company designs small interfering RNA therapeutics that provide durable gene suppression with infrequent dosing. City Therapeutics focuses on genetically validated targets and is advancing three lead liver-directed programs: CITY-FXI for thromboembolic disorders, CITY-RBP4 for Stargardt disease and retinal disorders, and CITY-TFR2 for anemia associated with myelofibrosis and other inflammatory conditions. In addition to liver-targeted therapies, City Therapeutics is developing proprietary delivery platforms to expand RNAi treatments to ocular and central nervous system tissues. Under its business model, City Therapeutics advances wholly owned candidates through Phase 2 clinical trials before partnering for late-stage development and commercialization. The company also monetizes its technology platform through research and licensing collaborations with pharmaceutical partners, including Bausch + Lomb and Biogen, earning milestone payments and royalties while outsourcing its manufacturing to third-party contract organizations.